{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:39:38Z","timestamp":1782315578064,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.trsl.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T20:02:58Z","timestamp":1742068978000},"page":"16-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Soluble ST2 is an early marker and treatment target for hypertensive nephrosclerosis signatured in glomerular mesangial cells"],"prefix":"10.1016","volume":"279","author":[{"given":"Jeong Min","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Joon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saram","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunhwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dha Woon","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran-hui","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kook-Hwan","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwon Wook","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yon Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hee","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2025.03.001_bib0001","unstructured":"United States Renal Data System. 2022 ADR chronic kidney disease."},{"key":"10.1016\/j.trsl.2025.03.001_bib0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2025.03.001_bib0003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ckj\/sfaa162","article-title":"Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology","volume":"13","author":"Carriazo","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trsl.2025.03.001_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ckj\/sfaa271","article-title":"The ERA-EDTA Registry Annual Report 2018: a summary","volume":"14","author":"Kramer","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trsl.2025.03.001_bib0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.2010.19","article-title":"Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy","volume":"77","author":"Middleton","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2025.03.001_bib0006","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.HYP.25.4.587","article-title":"Early predictors of 15-year end-stage renal disease in hypertensive patients","volume":"25","author":"Perry","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.trsl.2025.03.001_bib0007","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2025.03.001_bib0008","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1038\/s41598-020-62502-0","article-title":"ST2 and regulatory T cells in the colorectal adenoma\/carcinoma microenvironment: implications for diseases progression and prognosis","volume":"10","author":"Cui","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2025.03.001_bib0009","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.neuroscience.2017.11.028","article-title":"IL-33\/ST2 pathway as a rational therapeutic target for CNS diseases","volume":"369","author":"Du","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.trsl.2025.03.001_bib0010","doi-asserted-by":"crossref","first-page":"E2705","DOI":"10.1073\/pnas.1604032113","article-title":"IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline","volume":"113","author":"Fu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2025.03.001_bib0011","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/eji.202149175","article-title":"IL-33\/ST2 as a potential target for tumor immunotherapy","volume":"51","author":"Jiang","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0012","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.118.11157","article-title":"IL-33 (Interleukin 33)\/sST2 axis in hypertension and heart failure","volume":"72","author":"Ghali","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.trsl.2025.03.001_bib0013","first-page":"145","article-title":"Soluble ST2 testing: A promising biomarker in the management of heart failure","volume":"106","author":"Villacorta","year":"2016","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0014","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ehf2.14147","article-title":"Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy","volume":"10","author":"Wei","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.trsl.2025.03.001_bib0015","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/HJH.0b013e3283611bdf","article-title":"Soluble ST2 predicts elevated SBP in the community","volume":"31","author":"Ho","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.trsl.2025.03.001_bib0016","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jch.12205","article-title":"Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients","volume":"15","author":"Ojji","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.trsl.2025.03.001_bib0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ekir.2018.09.013","article-title":"Soluble ST2 and Galectin-3 and progression of CKD","volume":"4","author":"Alam","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.trsl.2025.03.001_bib0018","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10875-011-9622-7","article-title":"Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease","volume":"32","author":"Bao","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178939","article-title":"IL-33 and ST2 levels in chronic kidney disease: associations with inflammation, vascular abnormalities, cardiovascular events, and survival","volume":"12","author":"Gungor","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2025.03.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125282","article-title":"Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction","volume":"10","author":"Tung","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2025.03.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112705","article-title":"Role of the IL-33\/ST2 pathway in renal allograft rejection","volume":"405","author":"Yu","year":"2021","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.trsl.2025.03.001_bib0022","first-page":"897","article-title":"Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis","volume":"40","author":"Moreau","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.HYP.21.1.29","article-title":"Angiotensin II causes mesangial cell hypertrophy","volume":"21","author":"Anderson","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.trsl.2025.03.001_bib0024","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0272-6386(95)90001-2","article-title":"The link between hypertension and nephrosclerosis","volume":"25","author":"Freedman","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2025.03.001_bib0025","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1053\/j.ajkd.2016.02.035","article-title":"AJKD Atlas of Renal Pathology: arterionephrosclerosis","volume":"67","author":"Lusco","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2025.03.001_bib0026","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","year":"2013","journal-title":"Kidney international"},{"key":"10.1016\/j.trsl.2025.03.001_bib0027","doi-asserted-by":"crossref","first-page":"F809","DOI":"10.1152\/ajprenal.00037.2020","article-title":"RNA-seq profiling of microdissected glomeruli identifies potential biomarkers for human IgA nephropathy","volume":"319","author":"Park","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0028","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trsl.2025.03.001_bib0029","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.ki.5002118","article-title":"The ISN\/RPS 2003 classification of lupus nephritis: an assessment at 3 years","volume":"71","author":"Markowitz","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2025.03.001_bib0030","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1111\/jcmm.15636","article-title":"Urinary cMet as a prognostic marker in immunoglobulin A nephropathy","volume":"24","author":"An","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.trsl.2025.03.001_bib0031","doi-asserted-by":"crossref","first-page":"F505","DOI":"10.1152\/ajprenal.00533.2015","article-title":"Cln 3-requiring 9 is a negative regulator of Th17 pathway-driven inflammation in anti-glomerular basement membrane glomerulonephritis","volume":"311","author":"Lee","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111706","article-title":"Kr\u00fcppel-like factor 15 is a key suppressor of podocyte fibrosis under rotational force-driven pressure","volume":"386","author":"Yu","year":"2020","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.trsl.2025.03.001_bib0033","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/cells11050762","article-title":"Renoprotective effect of KLF2 on glomerular endothelial dysfunction in hypertensive nephropathy","volume":"11","author":"Bae","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.trsl.2025.03.001_bib0034","doi-asserted-by":"crossref","first-page":"F553","DOI":"10.1152\/ajprenal.00595.2020","article-title":"Blockade of STAT3 signaling alleviates the progression of acute kidney injury to chronic kidney disease through antiapoptosis","volume":"322","author":"Park","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/jhh.2013.55","article-title":"Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage","volume":"28","author":"Mennuni","year":"2014","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.trsl.2025.03.001_bib0036","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/joim.13146","article-title":"Hypertensive nephrosclerosis: wider kidney biopsy indications may be needed to improve diagnostics","volume":"289","author":"Hallan","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.trsl.2025.03.001_bib0037","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/ndt\/15.10.1515","article-title":"Hypertensive nephrosclerosis-a cause of end-stage renal disease?","volume":"15","author":"Luft","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2025.03.001_bib0038","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/01.HYP.0000145180.38707.84","article-title":"Pathophysiology of hypertensive renal damage: implications for therapy","volume":"44","author":"Bidani","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.trsl.2025.03.001_bib0039","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0b013e3283600f8c","article-title":"Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder","volume":"22","author":"Kopp","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.trsl.2025.03.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415936","article-title":"Hypertensive nephropathy: unveiling the possible involvement of hemichannels and pannexons","volume":"23","author":"Lucero","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2025.03.001_bib0041","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ki.1984.147","article-title":"Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats","volume":"26","author":"Raij","year":"1984","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2025.03.001_bib0042","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/ehf2.13883","article-title":"Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure","volume":"9","author":"Vergaro","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.trsl.2025.03.001_bib0043","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week","volume":"74","author":"Aimo","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0044","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/ijms18040783","article-title":"Emerging roles of IL-33\/ST2 axis in renal diseases","volume":"18","author":"Chen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2025.03.001_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0002-9440(10)63938-7","article-title":"Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence: a possible new mechanism for glomerulosclerosis","volume":"158","author":"Riser","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0046","doi-asserted-by":"crossref","first-page":"F688","DOI":"10.1152\/ajprenal.2000.279.4.F688","article-title":"Stretch-induced mesangial cell ERK1\/ERK2 activation is enhanced in high glucose by decreased dephosphorylation","volume":"279","author":"Dlugosz","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0047","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1210\/en.2003-0739","article-title":"Lisofylline, a novel antiinflammatory compound, protects mesangial cells from hyperglycemia- and angiotensin II-mediated extracellular matrix deposition","volume":"144","author":"Bolick","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.trsl.2025.03.001_bib0048","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00432305","article-title":"The glomerular mesangium in hypertension: a morphometrical comparison of nephrosclerosis with mesangioproliferative glomerulonephritis on renal biopsies","volume":"368","author":"Hara","year":"1975","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0049","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijbiomac.2016.05.002","article-title":"Bletilla striata polysaccharide inhibits angiotensin II-induced ROS and inflammation via NOX4 and TLR2 pathways","volume":"89","author":"Yue","year":"2016","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108191","article-title":"The IL-18\/IL-18R1 signalling axis: diagnostic and therapeutic potential in hypertension and chronic kidney disease","volume":"239","author":"Thomas","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.trsl.2025.03.001_bib0051","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ni.3370","article-title":"Interleukin 33 is a guardian of barriers and a local alarmin","volume":"17","author":"Martin","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0052","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","article-title":"Interleukin-33 in tissue homeostasis, injury, and inflammation","volume":"42","author":"Molofsky","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2025.03.001_bib0053","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000513663","article-title":"Soluble ST2 and Galectin-3 as predictors of chronic kidney disease progression and outcomes","volume":"52","author":"Kim","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0054","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/cvr\/cvq104","article-title":"Primary sources and immunological prerequisites for sST2 secretion in humans","volume":"87","author":"Mildner","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.trsl.2025.03.001_bib0055","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1165\/rcmb.2012-0406OC","article-title":"Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury","volume":"49","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.trsl.2025.03.001_bib0056","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1038\/s41467-020-18466-w","article-title":"IL-33-ST2 axis regulates myeloid cell differentiation and activation enabling effective club cell regeneration","volume":"11","author":"Dagher","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2025.03.001_bib0057","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/00313020701716367","article-title":"Differentiation of human mesenchymal stem cells into mesangial cells in post-glomerular injury murine model","volume":"40","author":"Wong","year":"2008","journal-title":"Pathology"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524425000350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524425000350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:16:11Z","timestamp":1746108971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524425000350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":57,"alternative-id":["S1931524425000350"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2025.03.001","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble ST2 is an early marker and treatment target for hypertensive nephrosclerosis signatured in glomerular mesangial cells","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}